Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eczema drug shows promise in Mid-Stage trial

NCT ID NCT06790121

Completed Symptom relief Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 22 times

Summary

This study tested a new drug called lunsekimig in 150 adults with moderate-to-severe eczema who did not get enough relief from topical treatments. Participants received one of three doses of the drug or a placebo as a shot under the skin for 24 weeks. The main goal was to see how much the eczema improved, measured by a standard skin score.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DERMATITIS, ATOPIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Beacon Clinical Research-Site Number: 8400006

    Quincy, Massachusetts, 02169, United States

  • Burien US-WA 98168 Dermatology of Seattle and Bellevue-Site Number: 8400015

    Burien, Washington, 98168, United States

  • Clinical Trials Management LLC-Site Number: 8400010

    Covington, Louisiana, 70433, United States

  • Clinical Trials Research Institute-Site Number: 8400003

    Thousand Oaks, California, 91320, United States

  • DS Research - Kentucky-Site Number: 8400005

    Louisville, Kentucky, 40241, United States

  • DermResearch-Site Number: 8400014

    Austin, Texas, 78759, United States

  • Driven Research LLC-Site Number: 8400020

    Coral Gables, Florida, 33134, United States

  • Health Concepts-Site Number: 8400025

    Rapid City, South Dakota, 57702, United States

  • Icahn School of Medicine at Mount Sinai-Site Number: 8400023

    New York, New York, 10029, United States

  • Indiana Clinical Trials Center, P.C.-Site Number: 8400018

    Plainfield, Indiana, 46168, United States

  • Integrative Skin Science and Research-Site Number: 8400002

    Sacramento, California, 95815, United States

  • Investigational Site Number: 0203001

    Prague, 128 00, Czechia

  • Investigational Site Number: 0203002

    Prague, 160 00, Czechia

  • Investigational Site Number: 0203003

    Prague, 101 00, Czechia

  • Investigational Site Number: 0203004

    Prague, 128 00, Czechia

  • Investigational Site Number: 3920001

    Ōta-ku, 160-0023, Japan

  • Investigational Site Number: 3920002

    Mibu, 321-0293, Japan

  • Investigational Site Number: 3920003

    Fukuoka, 812-8582, Japan

  • Investigational Site Number: 3920004

    Kofu, 400-8506, Japan

  • Investigational Site Number: 3920005

    Asahikawa-shi, 070-8610, Japan

  • Investigational Site Number: 3920006

    Nerima-ku, 177-0041, Japan

  • Investigational Site Number: 3920007

    Yokohama, 221-0825, Japan

  • Investigational Site Number: 3920008

    Tachikawa-shi, 190-0023, Japan

  • Investigational Site Number: 6160001

    Mikołów, 43-190, Poland

  • Investigational Site Number: 6160002

    Warsaw, 02-953, Poland

  • Investigational Site Number: 6160003

    Katowice, 40-748, Poland

  • Investigational Site Number: 6160004

    Szczecin, 70-332, Poland

  • Investigational Site Number: 6160005

    Wroclaw, 50-224, Poland

  • Investigational Site Number: 6160006

    Bydgoszcz, 85-231, Poland

  • Investigational Site Number: 6160007

    Katowice, 40-611, Poland

  • Investigational Site Number: 6160009

    Poznan, 60-192, Poland

  • Investigational Site Number: 6160010

    Jelenia Góra, 58-506, Poland

  • Investigational Site Number: 6160011

    Nowa Sól, 67-100, Poland

  • Investigational Site Number: 6160012

    Sosnowiec, 41-200, Poland

  • Investigational Site Number: 6160013

    Lublin, 20-011, Poland

  • Investigational Site Number: 6160014

    Bochnia, 32-700, Poland

  • Investigational Site Number: 6160015

    Ostrowiec Swietokrzyskie, 27-400, Poland

  • Investigational Site Number: 6160016

    Łodź, 91-495, Poland

  • Investigational Site Number: 6160017

    Warsaw, 01-142, Poland

  • Investigational Site Number: 6160018

    Warsaw, 02-172, Poland

  • Medisearch LLC-Site Number: 8400017

    Saint Joseph, Missouri, 64506, United States

  • Optima Research-Site Number: 8400019

    Plainfield, Indiana, 46168, United States

  • Options Research Group-Site Number: 8400012

    West Lafayette, Indiana, 47906, United States

  • Progressive Clinical Research-Site Number: 8400001

    San Antonio, Texas, 78213, United States

  • Red River Research Partners-Site Number: 8400008

    Fargo, North Dakota, 58103, United States

  • Revival Research Institute, LLC-Site Number: 8400021

    Evans, Georgia, 30809, United States

  • Skin Cancer and Dermatology Institute-Site Number: 8400011

    Reno, Nevada, 89509, United States

  • Skin Care Research-Site Number: 8400013

    Boca Raton, Florida, 33486, United States

  • Somerset Skin Centre-Site Number: 8400009

    Troy, Michigan, 48084, United States

  • Southern Indiana Clinical Trials-Site Number: 8400024

    New Albany, Indiana, 47150, United States

  • T. Joseph Raoof MD Inc-Site Number: 8400004

    Encino, California, 91436, United States

  • Treasure Valley Medical Research-Site Number: 8400026

    Boise, Idaho, 83706, United States

Conditions

Explore the condition pages connected to this study.

DERMATITIS, ATOPIC